|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio of ASP7035 in Patients with Nocturia Associated with Norturnal Polyuria
100 项与 Tacurion Pharma, Inc. 相关的临床结果
0 项与 Tacurion Pharma, Inc. 相关的专利(医药)
100 项与 Tacurion Pharma, Inc. 相关的药物交易
100 项与 Tacurion Pharma, Inc. 相关的转化医学